欧州の高活性API市場：分析・予測 (2023-2033年)

欧州の高活性APIの市場規模は、2023年の59億8,000万米ドルから、予測期間中はCAGR 10.57%で推移し、2033年には163億3,000万米ドルに達すると予測されています。

高活性API市場の拡大を後押しする主な要因は、癌の罹患率の上昇と、APIの治療用途の広がりです。

欧州の高活性API市場は、癌罹患率の増加とさまざまな治療領域におけるHPAPIの応用の拡大により、著しい成長を遂げています。同地域の強固な製薬産業は、高度なR&D施設と厳格な規制の枠組みに支えられており、市場開発を促進しています。欧州の主要企業は、需要の高まりに対応するため、製造能力や共同提携に多額の投資を行っています。さらに、革新的な技術とプロセスの採用により、高品質で安全なHPAPIの生産が保証されています。さらに、高活性化合物の取り扱いに精通し、安全性と環境規制の遵守を確保し、製薬企業の運営コストを削減する専門的な製造受託機関 (CMO) へのアウトソーシング傾向が強まっていることも、市場を後押ししています。

当レポートでは、欧州の高活性APIの市場を調査し、業界の動向、技術・特許の動向、法規制環境、市場成長促進要因・抑制要因、市場規模の推移・予測、主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

第1章 市場

• 動向：現在および将来の影響評価
  • トレンド1：高効能APIの封じ込め技術の進歩
  • トレンド2：高効能API製造ユニットへの投資の増加
  • トレンド3：製薬会社による高効能APIの生産のCDMOへのアウトソーシング
• サプライチェーン/価値概要
  • サプライチェーンとサプライチェーンにおけるリスク
  • バリューチェーン分析
• 価格分析
• 特許出願動向 (年・国別)
• 規制状況
• 主要な世界的出来事の影響分析：COVID-19
• 市場力学：概要
  • 市場促進要因
  • 市場機会
  • 市場抑制要因

第2章 地域

• 地域別概要
• 欧州
  • 地域概要
  • 市場成長推進因子
  • 市場課題
  • フランス
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • その他

第3章 市場：競合ベンチマーキング・企業プロファイル

• 次なるフロンティア
• 地理的評価
  • Almac Group
  • Axplora Group GmbH
  • BASF SE
  • CordenPharma International
  • Helsinn Healthcare SA.
  • ICROM
  • Lonza
  • Merck KGaA
  • Sterling Pharma SolutionsAlmac Group

第4章 調査手法

List of Figures

• Figure 1: Highly Potent API Market (by Region), $Billion, 2022-2033
• Figure 2: Highly Potent API Market, Recent Developments
• Figure 3: Highly Potent API Market: Value Chain Analysis
• Figure 4: Highly Potent API Market: Pricing Analysis
• Figure 5: Highly Potent API Market, Patent Analysis (by Year), January 2018-December 2023
• Figure 6: Highly Potent API Market, Patent Analysis (by Country), January 2018-December 2023
• Figure 7: Regulatory Framework for Highly Potent API
• Figure 8: Impact Analysis of Market Navigating Factors, 2022-2033
• Figure 9: Incidence of Cancer (by Region), Million, 2020-2040
• Figure 10: Europe Highly Potent API Market, $Billion, 2022-2033
• Figure 11: France Highly Potent API Market, $Billion, 2022-2033
• Figure 12: Germany Highly Potent API Market, $Billion, 2022-2033
• Figure 13: U.K. Highly Potent API Market, $Billion, 2022-2033
• Figure 14: Spain Highly Potent API Market, $Billion, 2022-2033
• Figure 15: Italy Highly Potent API Market, $Billion, 2022-2033
• Figure 16: Rest-of-Europe Highly Potent API Market, $Billion, 2022-2033
• Figure 17: Some of the Key Innovators in the Highly Potent API Landscape
• Figure 18: Highly Potent API Market: Geographical Assessment
• Figure 19: Strategic Initiatives, January 2021-December 2023
• Figure 20: Share of Strategic Initiatives
• Figure 21: Data Triangulation
• Figure 22: Top-Down and Bottom-Up Approach
• Figure 23: Assumptions and Limitations

List of Tables

• Table 1: Europe Highly Potent API Market Snapshot
• Table 2: Short-Term and Long-Term Opportunities and Risks (by Region)
• Table 3: Key Trends, Impact Analysis
• Table 4: Highly Potent API Market, Key Investment
• Table 5: Recent Innovations for Manufacturing and Handling of Highly Potent Drugs
• Table 6: Highly Potent API Market (by Region), $Billion, 2022-2033
• Table 7: Highly Potent API Market (by Country), $Billion, 2022-2033

Introduction to Europe Highly Potent API Market

The Europe highly potent API market is projected to reach $16.33 billion by 2033 from $5.98 billion in 2023, growing at a CAGR of 10.57% during the forecast period 2023-2033. The primary factors propelling the expansion of the highly potent API market are the rising incidence of cancer, which boosts the demand for highly potent APIs, and the broadening range of therapeutic applications for these APIs.

Market Introduction

The Europe Highly Potent API market is experiencing significant growth, driven by increasing cancer prevalence and the expanding application of HPAPIs in various therapeutic areas. The region's robust pharmaceutical industry, supported by advanced R&D facilities and stringent regulatory frameworks, enhances market development. Key players in Europe are investing heavily in manufacturing capabilities and collaborative partnerships to meet the rising demand. Additionally, the adoption of innovative technologies and processes ensures the production of high-quality, safe HPAPIs. The market is further fueled by the growing outsourcing trend to specialized contract manufacturing organizations (CMOs) with expertise in handling highly potent compounds, ensuring compliance with safety and environmental regulations, and reducing operational costs for pharmaceutical companies.

Market Segmentation:

Segmentation 1: by Country

• U.K.
• Germany
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Competitive Strategy: The highly potent API market has numerous established players with product and service portfolios. Key players in the Europe highly potent API market analysed and profiled in the study involve established players offering products and services of highly potent API.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, type portfolio, and market penetration.

Some prominent names in the market include:

• Almac Group
• Axplora Group GmbH
• BASF Pharma Solutions
• CordenPharma International
• Helsinn Healthcare SA.
• ICROM
• Lonza
• Merck KGaA
• Sterling Pharma Solutions

Table of Contents

Executive Summary

Scope and Definition

1 Markets

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Trend 1: Advancements in Containment Technologies for Highly Potent APIs
  • 1.1.2 Trend 2: Increasing Investment for Highly Potent API Manufacturing Units
  • 1.1.3 Trend 3: Pharmaceutical Companies Outsourcing Highly Potent APIs Production to CDMOs
• 1.2 Supply Chain /Value Overview
  • 1.2.1 Supply Chain and Risks within the Supply Chain
  • 1.2.2 Value Chain Analysis
• 1.3 Pricing Analysis
• 1.4 Patent Filing Trend (by Year, Country)
• 1.5 Regulatory Landscape
• 1.6 Impact Analysis for Key Global Events - COVID-19
• 1.7 Market Dynamics: Overview
  • 1.7.1 Market Drivers
    • 1.7.1.1 Increasing Incidence of Cancer Leading to Demand in the Adoption of Highly Potent APIs
    • 1.7.1.2 Advancements in Drug Delivery Technologies
    • 1.7.1.3 Expanding Therapeutic Applications of Highly Potent API
  • 1.7.2 Market Opportunities
    • 1.7.2.1 Growing Emphasis on Personalized Medicine
    • 1.7.2.2 Increasing Opportunities for Pharma Companies in Developing Markets
  • 1.7.3 Market Restraints
    • 1.7.3.1 Regulatory Complexity for Highly Potent APIs' Manufacturing
    • 1.7.3.2 High Development and Production Costs

2 Regions

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 France
  • 2.2.5 Germany
  • 2.2.6 U.K.
  • 2.2.7 Spain
  • 2.2.8 Italy
  • 2.2.9 Rest-of-Europe

3 Markets -Competitive Benchmarking & Company Profiles

• 3.1 Next Frontiers
• 3.2 Geographic Assessment
  • 3.2.1 Almac Group
    • 3.2.1.1 Overview
    • 3.2.1.2 Key Developments
    • 3.2.1.3 Top Products/Product/Service Portfolio
    • 3.2.1.4 Top Competitors
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Axplora Group GmbH
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products/Product/Service Portfolio
    • 3.2.2.3 Key Developments
    • 3.2.2.4 Top Competitors
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 BASF SE
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products/Product/Service Portfolio
    • 3.2.3.3 Key Developments
    • 3.2.3.4 Top Competitors
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 CordenPharma International
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products/Product/Service Portfolio
    • 3.2.4.3 Key Developments
    • 3.2.4.4 Top Competitors
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Helsinn Healthcare SA.
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products/Product/Service Portfolio
    • 3.2.5.3 Key Developments
    • 3.2.5.4 Top Competitors
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 ICROM
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products/Product/Service Portfolio
    • 3.2.6.3 Top Competitors
    • 3.2.6.4 Key Personnel
    • 3.2.6.5 Analyst View
  • 3.2.7 Lonza
    • 3.2.7.1 Overview
    • 3.2.7.2 Top Products/Product/Service Portfolio
    • 3.2.7.3 Key Developments
    • 3.2.7.4 Top Competitors
    • 3.2.7.5 Key Personnel
    • 3.2.7.6 Analyst View
  • 3.2.8 Merck KGaA
    • 3.2.8.1 Overview
    • 3.2.8.2 Top Products/Product/Service Portfolio
    • 3.2.8.3 Key Developments
    • 3.2.8.4 Top Competitors
    • 3.2.8.5 Key Personnel
    • 3.2.8.6 Analyst View
  • 3.2.9 Sterling Pharma Solutions
    • 3.2.9.1 Overview
    • 3.2.9.2 Top Products/Product/Service Portfolio
    • 3.2.9.3 Key Developments
    • 3.2.9.4 Top Competitors
    • 3.2.9.5 Key Personnel
    • 3.2.9.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast